

# Athanasios Anastasilakis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7000811/publications.pdf>

Version: 2024-02-01

146  
papers

4,226  
citations

147726

31  
h-index

138417

58  
g-index

149  
all docs

149  
docs citations

149  
times ranked

4980  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Features of 24 Patients With Reboundâ€Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1291-1296.	3.1	270
2	Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1591-1600.	3.1	241
3	Irisin in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 207-217.	1.5	179
4	Irisin in metabolic diseases. <i>Endocrine</i> , 2018, 59, 260-274.	1.1	178
5	Selenium Supplementation in the Treatment of Hashimoto's Thyroiditis: A Systematic Review and a Meta-analysis. <i>Thyroid</i> , 2010, 20, 1163-1173.	2.4	150
6	Clinical complications following thyroid fineâ€needle biopsy: a systematic review. <i>Clinical Endocrinology</i> , 2009, 71, 157-165.	1.2	149
7	Circulating Irisin in Healthy, Young Individuals: Day-Night Rhythm, Effects of Food Intake and Exercise, and Associations With Gender, Physical Activity, Diet, and Body Composition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3247-3255.	1.8	133
8	Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 264-281.	1.8	132
9	Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3Âmonths. <i>Osteoporosis International</i> , 2014, 25, 1633-1642.	1.3	111
10	Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2220-2228.	3.1	103
11	THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. <i>European Journal of Endocrinology</i> , 2018, 179, R31-R45.	1.9	94
12	Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 152.	1.0	89
13	Expression of microRNAs that regulate bone turnover in the serum of postmenopausal women with low bone mass and vertebral fractures. <i>European Journal of Endocrinology</i> , 2017, 176, 169-176.	1.9	86
14	Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 154005.	1.5	83
15	Multiple clinical vertebral fractures following denosumab discontinuation. <i>Osteoporosis International</i> , 2016, 27, 1929-1930.	1.3	75
16	Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. <i>European Journal of Endocrinology</i> , 2017, 176, 677-683.	1.9	70
17	Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 295.	0.9	69
18	Novel therapies for osteoporosis. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1199-1214.	1.5	62

#	ARTICLE	IF	CITATIONS
19	Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. <i>Metabolism: Clinical and Experimental</i> , 2017, 73, 1-8.	1.5	53
20	The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. <i>Clinical Endocrinology</i> , 2010, 72, 752-757.	1.2	52
21	Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. <i>Clinical Endocrinology</i> , 2013, 79, 499-503.	1.2	52
22	Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. <i>Osteoporosis International</i> , 2015, 26, 2521-2527.	1.3	49
23	Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1206-1213.	1.8	48
24	A Systematic Review of Cases Reporting Needle Tract Seeding Following Thyroid Fine Needle Biopsy. <i>World Journal of Surgery</i> , 2010, 34, 844-851.	0.8	46
25	Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3206-3212.	1.8	46
26	Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. <i>Archives of Osteoporosis</i> , 2017, 12, 58.	1.0	44
27	Clinical Efficacy and Safety of Denosumab in Postmenopausal Women with Low Bone Mineral Density and Osteoporosis: A Meta-Analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 178-186.	1.6	43
28	Bazedoxifene for the treatment of osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1201-1210.	0.9	42
29	Bone disease in primary hyperparathyroidism. <i>Metabolism: Clinical and Experimental</i> , 2018, 80, 57-65.	1.5	40
30	Denosumab Treatment for Juvenile Paget's Disease: Results From Two Adult Patients With Osteoprotegerin Deficiency (a Balkan Mutation in the <i>TNFRSF11B</i> Gene). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 703-707.	1.8	38
31	Off-label uses of denosumab in metabolic bone diseases. <i>Bone</i> , 2019, 129, 115048.	1.4	37
32	Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1441-1460.	1.8	35
33	Apelin levels in normal pregnancy. <i>Clinical Endocrinology</i> , 2011, 75, 367-371.	1.2	34
34	Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society. <i>Bone</i> , 2019, 127, 401-418.	1.4	33
35	Combination and sequential treatment in women with postmenopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 477-490.	0.9	33
36	Regulation of the activins-follistatins-inhibins axis by energy status: Impact on reproductive function. <i>Metabolism: Clinical and Experimental</i> , 2018, 85, 240-249.	1.5	32

#	ARTICLE	IF	CITATIONS
37	The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4155-e4162.	1.8	31
38	RANKL inhibition for the management of patients with benign metabolic bone disorders. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1085-1102.	1.9	30
39	Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. <i>Bone</i> , 2012, 50, 1130-1134.	1.4	30
40	Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation. <i>Rheumatology</i> , 2015, 54, 908-914.	0.9	30
41	Acute changes in serum osteoprotegerin and receptor activator for nuclear factor- $\kappa$ B ligand levels in women with established osteoporosis treated with teriparatide. <i>European Journal of Endocrinology</i> , 2008, 158, 411-415.	1.9	29
42	Serum leptin, adiponectin and ghrelin concentrations in post-menopausal women: Is there an association with bone mineral density?. <i>Maturitas</i> , 2016, 88, 32-36.	1.0	29
43	Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e390-e400.	1.8	29
44	Cost-effective osteoporosis treatment thresholds in Greece. <i>Osteoporosis International</i> , 2015, 26, 1949-1957.	1.3	28
45	The 2018 Guidelines for the diagnosis and treatment of osteoporosis in Greece. <i>Archives of Osteoporosis</i> , 2019, 14, 39.	1.0	28
46	Activin A and follistatin in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1550-1558.	1.5	27
47	Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 706-712.	1.3	26
48	The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. <i>Bone</i> , 2020, 138, 115478.	1.4	26
49	Circulating Periostin Levels do not Differ Between Postmenopausal Women with Normal and Low Bone Mass and are not Affected by Zoledronic Acid Treatment. <i>Hormone and Metabolic Research</i> , 2014, 46, 145-149.	0.7	25
50	The Effect of Leptin Replacement on Parathyroid Hormone, RANKL-Osteoprotegerin Axis, and Wnt Inhibitors in Young Women With Hypothalamic Amenorrhea. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2252-E2258.	1.8	25
51	Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1291-1297.	1.5	24
52	Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. <i>Journal of Bone and Mineral Metabolism</i> , 2016, 34, 447-456.	1.3	24
53	Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. <i>Hormones</i> , 2011, 10, 174-195.	0.9	23
54	Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation. <i>Bone Reports</i> , 2020, 12, 100267.	0.2	22

#	ARTICLE	IF	CITATIONS
55	Alterations in Serum Thyroid-Related Constituents After Thyroid Fine-Needle Biopsy: A Systematic Review. <i>Thyroid</i> , 2010, 20, 265-271.	2.4	21
56	Serum vaspin levels in normal pregnancy in comparison with non-pregnant women. <i>European Journal of Endocrinology</i> , 2011, 164, 579-583.	1.9	21
57	Coexistence of Graves™ disease, papillary thyroid carcinoma and unilateral benign struma ovarii: Case report and review of the literature. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1350-1356.	1.5	20
58	Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartum. <i>Cytokine</i> , 2013, 61, 127-132.	1.4	20
59	Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1459-1465.	1.5	19
60	Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. <i>Bone</i> , 2019, 120, 44-49.	1.4	19
61	Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations. <i>Maturitas</i> , 2021, 147, 19-25.	1.0	19
62	No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase Response. <i>Calcified Tissue International</i> , 2011, 88, 402-408.	1.5	18
63	Role of wingless tail signaling pathway in osteoporosis. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2011, 18, 383-388.	1.2	18
64	Oxidized low-density lipoprotein and adiponectin levels in pregnancy. <i>Gynecological Endocrinology</i> , 2011, 27, 1070-1073.	0.7	17
65	The effect of smoking on clinical and radiographic variables, and acute phase reactants in patients with ankylosing spondylitis. <i>Rheumatology International</i> , 2015, 35, 2109-2114.	1.5	17
66	Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 145-157.	1.9	17
67	Subendothelial Carotid Hematoma After Fine-Needle Aspiration Biopsy of a Solitary Thyroid Nodule. <i>Journal of Ultrasound in Medicine</i> , 2008, 27, 1517-1520.	0.8	16
68	Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease. <i>Endocrine</i> , 2015, 49, 560-562.	1.1	16
69	Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 299-306.	1.5	16
70	Endogenous Intact PTH is Suppressed during Teriparatide (rhPTH 1-34) Administration in Postmenopausal Women with Established Osteoporosis. <i>Endocrine Journal</i> , 2008, 55, 613-616.	0.7	15
71	Reduced bone mineral density in adult patients with Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2012, 58, 819-822.	0.8	15
72	Physiological parameters regulating circulating levels of the IGFBP-4/Stanniocalcin-2/PAPP-A axis. <i>Metabolism: Clinical and Experimental</i> , 2017, 75, 16-24.	1.5	15

#	ARTICLE	IF	CITATIONS
73	Acute transient thyroid swelling following needle biopsy: An update. <i>Hormones</i> , 2012, 11, 147-150.	0.9	14
74	Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. <i>Rheumatology International</i> , 2013, 33, 2917-2920.	1.5	14
75	Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis. <i>Metabolism: Clinical and Experimental</i> , 2017, 69, 107-111.	1.5	14
76	Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. <i>Supportive Care in Cancer</i> , 2009, 17, 1329-1330.	1.0	13
77	Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1137-1144.	1.9	13
78	Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment. <i>Osteoporosis International</i> , 2013, 24, 2127-2132.	1.3	12
79	Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview. <i>Hormones</i> , 2019, 18, 65-70.	0.9	12
80	The Impact of Antiosteoporotic Drugs on Glucose Metabolism and Fracture Risk in Diabetes: Good or Bad News?. <i>Journal of Clinical Medicine</i> , 2021, 10, 996.	1.0	12
81	Is Serum IL-17A a Useful Systemic Biomarker in Patients With Langerhans Cell Histiocytosis?. <i>Molecular Therapy</i> , 2012, 20, 6-7.	3.7	11
82	Bone metabolism in Langerhans cell histiocytosis. <i>Endocrine Connections</i> , 2018, 7, R246-R253.	0.8	11
83	Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. <i>Metabolism: Clinical and Experimental</i> , 2019, 93, 100-102.	1.5	11
84	Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2885-e2894.	1.8	11
85	Teriparatide Treatment in Patients with Pregnancy- and Lactation-Associated Osteoporosis. <i>Calcified Tissue International</i> , 2021, 109, 554-562.	1.5	11
86	Central skeletal sarcoidosis: a case report with sustained remission only on methotrexate, and a literature review on the imaging approach, treatment, and assessment of disease activity. <i>Modern Rheumatology</i> , 2013, 23, 175-181.	0.9	11
87	Paget's disease of bone: emphasis on treatment with zoledronic acid. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 423-434.	1.2	10
88	Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E618-E621.	1.8	10
89	Thiazolidinedione use and the risk of fractures. <i>Cmaj</i> , 2009, 180, 841-842.	0.9	9
90	A case report of subacute thyroiditis during pregnancy: difficulties in differential diagnosis and changes in cytokine levels. <i>Gynecological Endocrinology</i> , 2011, 27, 384-390.	0.7	9

#	ARTICLE	IF	CITATIONS
91	Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough. <i>Journal of Clinical Densitometry</i> , 2021, 24, 338-340.	0.5	9
92	No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial. <i>Clinical Endocrinology</i> , 2009, 70, 522-526.	1.2	8
93	Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 314-319.	1.3	8
94	Rationale for the Application of RANKL Inhibition in the Treatment of Langerhans Cell Histiocytosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E282-E286.	1.8	8
95	Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation. <i>Calcified Tissue International</i> , 2021, 108, 587-594.	1.5	8
96	Papillary thyroid microcarcinoma presenting as lymph node metastasis – a diagnostic challenge: case report and systematic review of literature. <i>Hormones</i> , 2012, 11, 419-427.	0.9	7
97	Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. <i>Calcified Tissue International</i> , 2018, 103, 107-108.	1.5	7
98	Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls. <i>Hormone and Metabolic Research</i> , 2019, 51, 112-119.	0.7	7
99	Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation. <i>Journal of Clinical Densitometry</i> , 2021, 24, 591-596.	0.5	7
100	Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients. <i>Bone Reports</i> , 2021, 15, 101128.	0.2	7
101	Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation. <i>Endocrine</i> , 2020, 69, 516-518.	1.1	7
102	Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases. <i>Hormones</i> , 2007, 6, 233-41.	0.9	7
103	The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass. <i>Clinical Endocrinology</i> , 2012, 77, 816-822.	1.2	6
104	Circulating periostin in patients with nonalcoholic fatty liver disease. <i>Endocrine</i> , 2017, 56, 438-441.	1.1	6
105	Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. <i>Hormones</i> , 2018, 17, 573-579.	0.9	6
106	Denosumab for the treatment of primary pediatric osteoporosis. <i>Osteoporosis International</i> , 2021, 32, 2377-2381.	1.3	6
107	Beyond glycemic control: New guidance on cardio-renal protection. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 113-115.	1.5	5
108	Gender Predisposition in Sporadic Parathyroid Adenomas. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2964.	1.8	5



#	ARTICLE	IF	CITATIONS
109	Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 108-110.	1.3	4
110	Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2010, 54, 578-582.	1.3	4
111	Denosumab and bisphosphonates: Rivals or potential "partners"? A "hybrid" molecule hypothesis. <i>Medical Hypotheses</i> , 2011, 77, 109-111.	0.8	4
112	Periostin on the road to nonalcoholic fatty liver disease. <i>Endocrine</i> , 2016, 51, 4-6.	1.1	4
113	Bisphosphonates or denosumab discontinuation and risk of fractures. <i>Maturitas</i> , 2017, 102, 75.	1.0	4
114	Management of parathyroid disorders: recommendations of the working group of the Bone Section of the Hellenic Endocrine Society. <i>Hormones</i> , 2020, 19, 581-591.	0.9	4
115	Parathyroid Disease in Pregnancy and Lactation: A Narrative Review of the Literature. <i>Biomedicines</i> , 2021, 9, 475.	1.4	4
116	Infectious thyroiditis as a complication of fine-needle biopsy: a systematic review. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 673-679.	1.2	3
117	Dual-Energy X-Ray Absorptiometry and Quantitative Ultrasound in Patients With Paget's Disease of Bone Before and After Treatment With Zoledronic Acid: Association With Serum Bone Markers and Dickkopf-1. <i>Journal of Clinical Densitometry</i> , 2010, 13, 190-196.	0.5	3
118	Adult Langerhans Cell Histiocytosis and the Skeleton. <i>Journal of Clinical Medicine</i> , 2022, 11, 909.	1.0	3
119	Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity. <i>Metabolism: Clinical and Experimental</i> , 2017, 71, 198-201.	1.5	2
120	Hypoparathyroidism: is it that easy to treat?. <i>Hormones</i> , 2019, 18, 55-63.	0.9	2
121	Î™risin levels in postmenopausal women with an incident hip fracture. <i>Endocrine</i> , 2021, 73, 719-722.	1.1	2
122	Irisin in nonalcoholic fatty liver disease: need for an updated meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2021, 121, 154818.	1.5	2
123	Questions and facts regarding denosumab discontinuation among postmenopausal women. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 499-501.	1.0	2
124	Periostin and sclerostin levels in juvenile Paget's disease. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2017, 14, 269.	1.0	2
125	The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis. <i>Bone</i> , 2022, 158, 116354.	1.4	2
126	The effect of zoledronic acid on serum Dickkopf-1, osteoprotegerin and rankl in patients with paget's disease of bone. <i>Bone</i> , 2009, 44, S289.	1.4	1



#	ARTICLE	IF	CITATIONS
127	Disease-modifying anti-rheumatic drugs for refractory severe knee synovitis in patients with peripheral spondyloarthritis: efficacy and predictors of response. Scandinavian Journal of Rheumatology, 2013, 42, 369-372.	0.6	1
128	Serum sclerostin levels following treatment with parathyroid hormone. Journal of Endocrinological Investigation, 2013, 36, 280-280.	1.8	1
129	Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying Antirheumatic Drugs in Patients with Peripheral Spondyloarthritis. ISRN Rheumatology, 2013, 2013, 1-4.	1.9	1
130	Fracture risk among treatment-naïve postmenopausal women with osteopenia in Greece: results from the "ACROSS" study. Archives of Osteoporosis, 2020, 15, 163.	1.0	1
131	Circulating and Tissue Expression Profile of MicroRNAs in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas. JBMR Plus, 2021, 5, e10431.	1.3	1
132	Authors' Response to Dr. Lutz Schomburg. Thyroid, 2011, 21, 564-565.	2.4	0
133	THU0080...Association of Serum Periostin Levels with Disease Activity and Radiographic Damage, as Well as Serum Bone Formation Markers, in Patients with Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 2014, 73, 204.2-204.	0.5	0
134	P1017 : Circulating sclerostin and DICKKOPF-1 in patients with Nonalcoholic Fatty Liver Disease. Journal of Hepatology, 2015, 62, S729.	1.8	0
135	Development and validation of an osteoporosis treatment questionnaire (OSTREQ) evaluating physicians' criteria in the choice of treatment. Hormones, 2016, 15, 413-422.	0.9	0
136	Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion. Endocrine, 2021, 73, 223-225.	1.1	0
137	Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartum. Endocrine Abstracts, 0, , .	0.0	0
138	Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Bone Abstracts, 0, , .	0.0	0
139	Circulating microRNAs in postmenopausal women with osteoporosis and vertebral fractures. Bone Abstracts, 0, , .	0.0	0
140	Serum leptin, adiponectin and ghrelin concentrations in post-menopausal women: is there an association with bone mineral density?. Endocrine Abstracts, 0, , .	0.0	0
141	Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid. Journal of Clinical Endocrinology and Metabolism, 2016, 101, L89-L90.	1.8	0
142	Annual Seminar of Hellenic Osteoporosis Foundation The role of mechanical factors on the musculoskeletal system. Journal of Frailty, Sarcopenia and Falls, 2016, 01, 58-72.	0.4	0
143	Serum and tissue expression profile of microRNAs that regulate genes related to the pathogenesis of sporadic parathyroid adenomas. Endocrine Abstracts, 0, , .	0.0	0
144	SUN-LB65 Circulating Micrnas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis. Journal of the Endocrine Society, 2020, 4, .	0.1	0

#	ARTICLE	IF	CITATIONS
145	Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2019, 19, 253-257.	0.1	0
146	Response to Letter to the Editor From Taguchi: “Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS”, <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	1.8	0